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Abstract
MicroRNAs (miRNAs) play important roles in diverse biological processes and are emerging as key regulators of
tumorigenesis and tumor progression. To explore the dysregulation of miRNAs in breast cancer, a genome-wide
expression profiling of 939 miRNAs was performed in 50 breast cancer patients. A total of 35 miRNAs were
aberrantly expressed between breast cancer tissue and adjacent normal breast tissue and several novel miRNAs
were identified as potential oncogenes or tumor suppressor miRNAs in breast tumorigenesis. miR-125b exhibited the
largest decrease in expression. Enforced miR-125b expression in mammary cells decreased cell proliferation by
inducing G2/M cell cycle arrest and reduced anchorage-independent cell growth of cells of mammary origin.
miR-125b was found to perform its tumor suppressor function via the direct targeting of the 3’-UTRs of ENPEP, CK2-
α, CCNJ, and MEGF9 mRNAs. Silencing these miR-125b targets mimicked the biological effects of miR-125b
overexpression, confirming that they are modulated by miR-125b. Analysis of ENPEP, CK2-α, CCNJ, and MEGF9
protein expression in breast cancer patients revealed that they were overexpressed in 56%, 40–56%, 20%, and 32%
of the tumors, respectively. The expression of ENPEP and CK2-α was inversely correlated with miR-125b expression
in breast tumors, indicating the relevance of these potential oncogenic proteins in breast cancer patients. Our results
support a prognostic role for CK2-α, whose expression may help clinicians predict breast tumor aggressiveness. In
particular, our results show that restoration of miR-125b expression or knockdown of ENPEP, CK2-α, CCNJ, or
MEGF9 may provide novel approaches for the treatment of breast cancer.
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Introduction
The incidence of malignancy is increasing worldwide, to such
an extent that cancer has replaced heart disease as the
leading cause of disease-related mortality [1]. Breast cancer is
the second leading cause of cancer-related deaths in the USA
and Europe. Mortality from this disease remains high because
current therapies are limited by the emergence of therapy-
resistant cells [2].
miRNAs are small (18- to 25-nucleotide-long) single-
stranded noncoding RNAs that regulate gene expression at the
posttranscriptional level by binding to the 3'-UTR of the target
messenger RNA (mRNA), thereby causing translational
repression or degradation. However, some miRNAs have been
shown to bind to the open reading frame, the 5’-UTR, or the
promoter of the target mRNA to cause downregulation or
upregulation of gene expression [3-7]. Thus, miRNAs are
considered key regulators of gene expression at transcriptional
and posttranscriptional levels. In addition, miRNAs play
essential roles in the regulation of biological processes,
including cell proliferation, stemness, differentiation, and
apoptosis.
In general, miRNA genes are frequently located in cancer-
associated genomic regions or fragile sites that are prone to
PLOS ONE | www.plosone.org 1 October 2013 | Volume 8 | Issue 10 | e76247
genetic and epigenetic alterations [8]. Altered miRNA
expression levels have been reported in most human cancers.
In fact, miRNAs can function as oncogenes or as tumor
suppressor genes by targeting different steps of the
tumorigenesis process, such as initiation, progression, and
metastasis [9,10]. Recently, miRNA profiling studies have led
to the identification of miRNAs that are aberrantly expressed in
breast cancer [11]. A complete identification of mRNA/miRNA
expression-based breast cancer subtypes will allow the
prediction of prognosis, therapy response, and resistance
development.
The goal of this study was to determine the most important
miRNAs that are altered in breast tumorigenesis and to find an
association between these miRNAs and novel proteins
involved in cancer signaling pathways. In this study, we have
proposed a breast cancer miRNA signature and have identified
novel miRNAs that are related to breast tumorigenesis.
According to our results, miR-125b was the most
downregulated miRNA in breast tumors. miR-125b represents
a paradoxical miRNA because its phenotypic effects differ
considerably, depending on cell type. Thus, miR-125b can
function as a tumor suppressor miRNA in many tumor types,
including ovarian cancer, hepatocellular carcinoma, melanoma,
bladder cancer, glioma, colorectal cancer, breast cancer and
osteosarcoma [12-19]. However, miR-125b may have a tumor-
promoting function in other types of cancer, including prostate
cancer [20] and leukemia [21].
Another goal of this study was to functionally characterize
the previously reported tumor suppressor role of miR-125b in
breast tumorigenesis [18]. Our experiments show that induced
expression of miR-125b in cells of mammary origin decreased
cell proliferation and anchorage-independent cell growth.
Accordingly, we show for the first time that miR-125b performs
its antiproliferative function by directly binding to the 3’-UTR
mRNAs of several uncharacterized genes, such as cyclin J
(CCNJ) and multiple EGF-like-domains 9 (MEGF9). Moreover,
miR-125b also downregulates other proteins whose roles in
tumorigenesis are not well defined, such as glutamyl
aminopeptidase or aminopeptidase A (ENPEP), and casein
kinase 2-alpha (CK2-α). Finally, we analyzed the protein
expression of ENPEP, CK2-α, CCNJ, and MEGF9 in breast
cancer patients. The prognostic role of ENPEP, CK2-α, CCNJ,




Written informed consent was obtained from each patient for
the analysis of both normal and tumor tissue. All of the
procedures performed in this study were approved by the
Ethics Committee of Vall d’Hebron Hospital. All of the patients
included in this study had been diagnosed with sporadic breast
cancer, and they were followed for a minimum of 2–3 years. No
patients in this study had been previously treated with chemo-/
radiotherapy prior to surgery, and the primary tumors were
isolated in all cases. For each patient, the following
pathological parameters were studied: age (<60 versus >60),
tumor size, tumor grade, the presence and number of lymph
node metastases, and the presence of distant metastases. The
molecular classifications of the tumors were luminal A (42%),
luminal B (38%), HER2+ (6%), and triple negative (14%).
A comprehensive miRNA profiling study was performed with
frozen normal and tumor tissues from 50 patients with breast
cancer (series 1). The tumor slides from all patients included in
this study were stained with hematoxylin-eosin and were
independently reviewed by pathologists to ensure that the
tissues, which had been stored at -80°C, had adequate (>80%)
tumor densities. Normal tissues from the same patients were
stained with hematoxylin-eosin to ensure an adequate content
of epithelial cells. Normal tissue could not be obtained from all
50 patients who were selected for our study. Therefore, normal
tissue samples from a total of 24 out of 50 patients (pools: A, B
and C; each pool comprised 8 patients) were analyzed.
An independent series of 50 additional patients (series 2),
who were sorted into pools, was also studied. Two pools of
miRNA samples were obtained from the second series of
patients. One pool was from breast cancer tissue (50 patients)
and the other pool was from the available normal tissue (20 out
of 50 patients). Moreover, 25 additional breast cancer patients
with similar pathological characteristics were selected for
miRNA and protein expression analysis (series 3). In series 3,
normal tissue was available for all 25 patients.
The biopsies were retrieved from the Tumor Bank in the
Pathology Department of Vall d’Hebron Hospital and diagnosed
at the Vall d’Hebron Hospital between 2007 and 2009.
RNA isolation, reverse transcription, and quantitative
real-time polymerase chain reaction
The frozen normal and tumor tissues were collected for RNA
extraction. The total RNA from the different breast cancer cells
used for this study and the patient biopsies were isolated with
the mirVana kit (Ambion, Austin, TX, USA) according to the
manufacturer’s instructions. Reverse transcription was
performed by using total RNA with stem-loop RT specific
primers for miR-125b or endogenous control small nuclear
RNU24 (RNU24) and the TaqMan MicroRNA Reverse
Transcription kit (Applied Biosystems, Foster City, CA, USA).
miRNA expression was measured by quantitative real-time
polymerase chain reaction (qRT-PCR) with a specific TaqMan
MicroRNA Assay (20X; forward primer, reverse primer, and
probe) for miR-125b (ID: 000449) and RNU24 endogenous
control (ID: 001001) and assayed on an ABI Prism 7500
System (Applied Biosystems) with cycling conditions of 95°C
for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for
60 s. The qRT-PCR was conducted in triplicate. The Ct (cycle
threshold) values of RNU24 were not different between the
tumors and the normal breast tissue samples (as detected by
qRT-PCR). The Ct values also did not differ among the cell
lines studied (data not shown). Relative expression of
miR-125b normalized to RNU24 was calculated with the 2-ΔΔCt
method.
miRNA microarray preparation
The human miRNA arrays (Agilent, Santa Clara, CA, USA)
containing 13,737 probes for 939 miRNAs were hybridized with
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the miRNA fraction from the normal and tumor tissues of 50
breast cancer patients (series 1). Briefly, 500 ng of total RNA
from each sample was chemically labeled by
dephosphorylation with calf intestinal alkaline phosphatase
(CIP) and ligation of cyanine3 (pCp) with T4-RNA ligase by
using the Agilent miRNA Complete Labeling and Hyb Kit (p/
n5190-0456; Agilent). The labeled RNA samples were dried,
resuspended in 18 l of nuclease-free water, and cohybridized
with the miRNA array in in situ hybridization buffer for 20 h at
55°C. The samples were then washed at room temperature for
5 min in gene expression wash buffer 1 and 5 min at 37°C in
gene expression wash buffer 2. Images of the samples were
generated on a confocal microarray scanner (G2565BA;
Agilent) at 5 µm resolution and quantified with the feature
extraction software (Agilent). Array data have been submitted
to the Gene Expression Omnibus dataset (accession number
GSE44124).
A different miRNA array platform (FEBIT, Heidelberg,
Germany) was used to validate our results with an independent
series of patients (series 2). The protocols for the sample
preparation and analysis of this array platform are described
elsewhere [22,23].
Immunohistochemistry
The CK2-α protein was studied by immunohistochemistry
(IHC) in the 50 patient samples included in the miRNA array
(series 1). Paraffin-embedded biopsies were studied for IHC,
and the IHC study was performed in tissue microarrays
(TMAs). The TMAs were conducted in quadruplicate by
extracting tissue cores from the original paraffin-embedded
biopsies as previously described [23]. Paraffin-embedded,
formalin-fixed tissue was cut into 5 µm sections, placed on
polylysine-coated slides, deparaffinized in xylene, and
rehydrated through a graded ethanol series. Endogenous
peroxidase activity was quenched in 0.3% hydrogen peroxide,
and the tissue was subjected to antigen retrieval treatment by
microwave heating in 10 mM citrate buffer (pH 6.0). The
sections were incubated at 4°C overnight with the CK2-α
antibody (Bethyl Laboratories, Montgomery, TX, USA). The
immunostaining was performed with the ChemMate DAKO
EnVision Detection Peroxidase/DAB kit (Dako, Glostrup,
Denmark), which resulted in a brown-colored precipitate at the
antigen site. Subsequently, the sections were counterstained
with hematoxylin-eosin and mounted in nonaqueous mounting
medium (Zymed Laboratories, San Francisco, CA, USA). CK2-
α was validated by using the histoscore system, as previously
described for other antibodies [22]. CK2-α expression was
considered positive when more than 50% of the tumor cells in
the biopsy stained positive (score > 60).
Cell culture
Human mammary epithelial cells (HMEC) were obtained
from Lonza (Lonza, Basel, Switzerland). MCF7, MDA-MB-231,
and MDA-MB-435 cells were obtained from the American Type
Culture Collection (ATCC, Manassas, VA, USA). The HMEC
were grown in mammary epithelium basal media (Lonza)
supplemented with MEGM SingleQuots (Lonza). The MCF7
and MDA-MB-435 cells were grown in Dulbecco’s Modified
Eagle’s Medium (Lonza), and the MDA-MB-231 cells were
grown in RPMI-1640 medium (Lonza). Both media were
supplemented with 10% fetal bovine serum, 100 U/ml penicillin,
and 100 µg/ml streptomycin. All of the cells were grown at 37°C
in a humidified incubator with 5% CO2. The cells were
passaged regularly at subconfluence.
Plasmid construction
For the miR-125b overexpression experiments, pre-
miR-125b was cloned into retroviral vector miR-Vec, which was
kindly donated by Dr. R. Agami (Netherlands Cancer Institute,
Amsterdam). Approximately 500 nt of the genomic DNA
sequence that encodes for primary miR-125b and its natural
flanking sequences was selected for PCR amplification,
according to a previously described procedure [24]. Primers
are detailed in Table S1.
For the luciferase assay, a reporter vector consisting of the
luciferase coding sequence followed by the wild-type or mutant
3’-UTR of putative targets of miR-125b was constructed. The
3’-UTRs of ENPEP (945 nt), CK2-α (1245 nt), CCNJ (916 nt),
and MEGF9 (2061 nt), which contain the predicted miR-125b
binding sites, were amplified by PCR from the normal tissues
and cloned into the previously described pCI vector [25].
Primers are described in Table S1. In all cases, the cloned
PCR products were validated by sequencing (data not shown).
Site-directed mutagenesis
The QuikChange II XL Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA, USA) was used to introduce point
mutations into the 3’-UTRs of human ENPEP, CK2-α, CCNJ,
and MEGF9. The following point mutations were introduced: at
position 202 of the 3’-UTR-ENPEP, at positions 210 and 450 of
the 3’-UTR-CK2-α, at position 714 of the 3’-UTR-CCNJ, and at
three different positions—416, 654, and 1721—of the 3’-UTR-
MEGF9. A different mutant plasmid was constructed for each
binding site located at the 3’-UTR mRNA predicted for
miR-125b. Primers are described in Table S1.
The PCR reaction was prepared by adding 5 µl of 10X
reaction buffer, 20 ng of dsDNA template, 125 ng each of the
sense and antisense primers, 1 µl of deoxyribonucleotide
triphosphate mix, 3 µl of QuickSolution, 1 µl of Pfu Ultra HF
DNA polymerase (2.5 U/µl), and double-distilled water to a final
volume of 50 µl. The PCR was performed with 18 cycles (95°C
for 50 s; 60°C for 50 s; and 68°C for 1 min/kb of the plasmid
length), including an initial incubation at 95°C for 1 min and a
final extension period at 68°C for 7 min. After the PCR reaction,
1 µl of the DpnI restriction enzyme (10 U/µl) was added directly
to each amplification reaction and incubated at 37°C for 1 h to
digest the parental supercoiled dsDNA. The DpnI-treated
dsDNA was transformed into XL10-Gold Ultracompetent cells.
The colonies selected were expanded in culture for DNA
extraction and the presence of the mutation was confirmed by
subsequent sequencing (data not shown).
Bioinformatics searches
Potential miR-125b targets were predicted and analyzed by
using publicly available algorithm-based databases, including
PicTar (http://pictar.mdc-berlin.de/), TargetScan (http://
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www.targetscan.org/), miRanda (http://www.microrna.org/), and
DIANA-microT (http://diana.cslab.ece.ntua.gr/). To select the
putative miR-125b mRNA targets, two different criteria were
used. The first criterion consisted of selecting mRNAs that are
predicted to be targets of miR-125b by more than one miRNA
database. Of these ENPEP, CK2-α, and MEGF9 were
selected. The second criterion consisted of selecting mRNAs
with a high score (p value) according to the TargetScan
database. Based on the latter criterion, CCNJ was selected.
For both criteria, those mRNAs that may be involved in cell
proliferation were considered for protein studies.
Transfection
For the stable expression of miRVec-125b or miRVec-GFP
(control cells), 30 µg of each retroviral vector was transfected
into Phoenix cells in 10-cm culture plates with FuGENE
(Roche, Basel, Switzerland). The viral supernatant was
harvested 48 h after transfection to infect HMEC, MCF7, and
MDA-MB-231 cells. Each stably transduced cell line was
selected with blasticidin (3 µg/ml for HMEC, 10 µg/ml for
MCF7, and 10 µg/ml for MDA-MB-231) for 12 days.
For anti-miR-mediated silencing of miR-125b, MDA-MB-435
and MCF7 cells were seeded at 2.5 × 105 and 2.0 × 105 cells
per well, respectively, in 6-well plates and transiently
transfected with anti-125b (ID: AM10148; Ambion) or a Cy3
dye-labeled negative control (ID: AM17010; Ambion) to a final
concentration of 80 nM with the HiPerFect reagent (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions.
At 72 h after transfection, the cells were counted and imaged,
and the cellular lysates were collected for analysis of the
protein expression of the selected putative miR-125b targets.
The transfection efficiency was determined by fluorescence
microscopy with the Cy3 dye-labeled negative control.
The knockdown experiments for ENPEP, CK2-α, CCNJ, and
MEGF9 were performed in MCF7 cells. MCF7 cells were
seeded at 2 × 105 cells per well in a 6-well plate and were
transiently transfected with pools of siRNAs (siGENOME
SMARTpool) against ENPEP (M-005865-01-0005), CK2-α
(M-003475-03), CCNJ (M-020397-01-0005), and MEGF9
(M-026241-01-0005) or a pool of negative control siRNAs
(siGENOME Non-Targeting siRNA Pool #1; 0-001206-13-05)
(Dharmacon, Lafayette, CO, USA) at a final concentration of 30
nM with the HiPerFect transfection reagent (Qiagen) according
to the manufacturer’s protocol. Each siRNA pool contained a
mixture of three different siRNAs for each gene. To control for
transfection efficiency, in addition to the Cy3-labeled control
siRNA, polo-like kinase 1 (PLK1) siRNA (ON-TARGET plus
SMART pool; Dharmacon L-003290-00-0005) was also
included (data not shown). The transfected cells were
incubated at 37°C for 72 h, counted, and collected for protein
extraction.
To study the long-term effects of gene silencing, MCF7 cells
were seeded at 2 × 105 cells per well in a 6-well plate and
stably transfected the following day with 3 µg of puromycin-
resistant SureSilencing™ shRNA plasmids. For each gene,
four different shRNAs were tested independently (No. 1, No. 2,
No. 3, and No. 4). The shRNAs for ENPEP (ID: KH02578P;
Qiagen), CK2-α (ID: KH01514P; Qiagen), CCNJ (ID:
KH15834P; Qiagen), MEGF9 (ID: KH14779P; Qiagen), and the
negative control shRNA plasmid NEG1-P (Sc) (ID: KA-001P;
Qiagen) were transfected with jetPEI transfection reagent
(Genycell, Granada, Spain) according to the manufacturer’s
instructions. To generate stably transfected cells, MCF7 cells
were selected with puromycin (1 µg/ml) (Sigma-Aldrich, St.
Louis, MO, USA) for 3 days. The growth curve analyses and
protein extractions were performed as previously described
[22]. Parental MCF7 cells (uninfected/untransfected) were
included in all experiments.
Growth curves
HMEC, MCF7, and MDA-MB-231 cells were seeded at 1 ×
106 cells per 10-cm plate. Parental cells for each cell line
(uninfected), the control cells (miRVec-GFP-infected), and cells
that expressed miRVec-125b were grown simultaneously.
Every 3 days, the cells from each cell line were counted and
reseeded at a density of 1 × 106 cells per 10-cm plate, as
indicated by the 3T3 protocol. In addition, 5 × 104 cells per well
were reseeded every 3 days in 24-well plates in triplicate and
fixed. Cell staining was performed with crystal violet.
Soft agar colony formation assay
For the soft agar colony formation assay, MCF7 and MDA-
MB-231 cells that expressed the control miRVec-GFP or
miRVec-125b were seeded in triplicate at a density of 5 × 104
cells/well in 6-well plates that contained medium with 1.4% D-1
Low EEQ agarose (Pronadisa, Madrid, Spain). The culture
medium was changed every 3 days, and the colonies were
counted and imaged after 20 days in culture.
Cell cycle analysis
For the cell cycle analysis, a fluorescence-activated cell
sorting Calibur flow cytometer (FACS Calibur Becton
Dickinson, E0772; BD Biosciences, San Jose, CA, USA) was
used to analyze HMEC, MCF7, and MBA-MB-231 cells that
stably expressed control miRVec-GFP or miRVec-125b. The
siRNA- and shRNA-transfected cells (si/shENPEP, si/shCK2-α,
si/shCCNJ, and si/shMEGF9) were also analyzed by FACS.
One million cells from each sample were fixed in 70% ethanol
for 15 min at -20°C, treated with 100 µg/ml RNase A (Sigma-
Aldrich), and stained with 50 µg/ml of propidium iodide (Sigma-
Aldrich). For each sample, 2 × 104 cells were analyzed, and the
percentage of cells in each phase of the cell cycle was
calculated based on the DNA content determined with FACS
Express Software.
Annexin V-APC apoptosis analysis
HMEC, MCF7, and MDA-MB-231 cells were infected with
miRVec-125b or miRVec-GFP and were selected with
blasticidin for stable expression. The analysis of apoptotic cells
was performed with the Annexin V-APC Detection Kit
(eBioscience, San Diego, CA, USA) according to the
manufacturer’s instructions. The samples were then analyzed
by FACS. For each sample, 2 × 104 cells were collected and
the results were analyzed with the FACS Express Software.
The siRNA- and shRNA-transfected cells (si/shENPEP, si/
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shCK2-α, si/shCCNJ, and si/shMEGF9) were also analyzed for
the presence or absence of apoptosis. The results were
confirmed in at least three independent experiments.
Analysis of senescence
Senescence-associated β-galactosidase (SA--gal) activity
was analyzed with a senescence β-galactosidase commercial
assay according to the manufacturer’s instructions (Cell
Signaling, Danvers, MA, USA), as previously described [26].
Senescence controls were included as indicated.
Luciferase reporter assay
The luciferase experiments were performed in HEK293T
cells. HEK293T cells were seeded at 1.4 × 105 cells per well in
a 24-well plate and were transfected the following day with
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) with the
following molecules: the synthetic miRNA precursors to
miR-125b (miR-125b mimics) (ID: PM10148; Ambion),
anti-125b (ID: PM10149; Ambion), or scrambled negative
control 1 (ID: AM17110; Ambion); and the wild-type luciferase
constructs cloned in the pCI plasmid: pCI versus pCI-3’-UTR-
ENPEP, pCI-3’-UTR-CK2-α, pCI-3’-UTR-CCNJ, or pCI-3’-UTR-
MEGF9; Renilla (PGL3-Pm) for normalization of transfection
efficiency; and pBluescript for DNA content normalization. The
transfection efficiency was approximately 95%, and luciferase
activity was measured 48 h after transfection with the dual-
luciferase reporter assay as described by the manufacturer
(Promega, Fitchburg, WI, USA).
In each case, the different miR-mimics/anti-miR
concentrations were measured by titrating the miR-mimics/anti-
miR with each pCI-3’-UTR mRNA construct to establish a
dose-response relationship between 10–80 nM (data not




MEGF9—or their respective wild-type pCI-3’-UTR mRNA was
performed with miR-125b mimics or scrambled negative control
in HEK293T cells. All transfection experiments were conducted
in triplicate and repeated at least 3 times independently.
Immunoblotting
Total cell lysates were prepared from a confluent 10-cm dish.
The cells were washed in PBS and lysed in 1 ml of lysis buffer
(50 mM Tris-HCl, pH 7.5, 1% NP-40, 10% glycerol, 150 mM
NaCl, plus 2 mM complete protease inhibitor cocktail) (Roche
Diagnostics, Barcelona, Spain). From each sample, 50 µg of
protein, which was previously quantified with the Bio-Rad
protein assay (Bio-Rad, Hercules, CA, USA), was then
analyzed by gel electrophoresis on a 6–12% SDS-
polyacrylamide gel and transferred onto a nitrocellulose
membrane. The following antibodies were used for western blot
analysis: ENPEP (Novus Biologicals, Littleton, CO, USA),
MEGF9 (Abcam, Cambridge, UK), CK2-α (Bethyl
Laboratories), CCNJ (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), CCND1 (Santa Cruz Biotechnology), CCNB1 (Santa
Cruz Biotechnology), and -actin (Sigma-Aldrich). In all cases,
the membranes were incubated overnight at 4°C with the
primary antibodies in PBS with 5% nonfat dry milk. The
membranes were then extensively washed with PBS and
incubated with horseradish peroxidase-conjugated anti-mouse
or anti-rabbit secondary antibody (Sigma-Aldrich). After
additional washes with PBS, the antigen-antibody complexes
were visualized with an enhanced chemiluminescence kit
(Millipore, Billerica, MA, USA).
Statistical analysis
Data analysis was performed with SPSS statistical software
(version 11.0; SPSS, Chicago, IL, USA). The analysis of the
miRNA array was performed as previously described [27] (p <
0.05 was considered significant). To establish the miRNA
signature, miRNAs that were differentially expressed between
the two classes of tissues were compared with a t-test (p <
0.01 was considered significant). To compare the expression of
miR-125b by qRT-PCR in normal and tumor tissues, a Mann-
Whitney test or Wilcoxon test was used as appropriate.
Luciferase experiments were analyzed by a Student’s t-test.
Lastly, a Pearson’s correlation test was used to compare the
pathological variables with the levels of ENPEP, CK2-α, CCNJ,
and MEGF9 protein expression and miR-125b expression (p <
0.05 was considered significant).
Results
miRNA expression profile in breast tumors
A comprehensive panel of 939 miRNAs (Agilent) was
analyzed in 50 breast cancer tumor samples, which were
compared with three pools of normal breast tissue from the
same patients (series 1; see Materials and Methods). A total of
35 miRNAs were dysregulated in the tumor sample compared
with normal breast tissue (Figure 1A, Table S2). These
miRNAs comprise two different classes, namely oncogenic and
tumor suppressor miRNAs. The 9 putative oncogenic miRNAs
were miR-21, miR-96, miR-141, miR-1274a, miR-1260,
miR-106b, miR-1274b, miR-130b, and miR-340. The 26
putative tumor suppressor miRNAs were miR-125b, miR-451,
miR-99a, miR-145, miR-100, miR-195, miR-497, miR-551b,
miR-376c, miR-486-5p, miR-204, miR-218, miR-381,
miR-139-5p, miR-489, miR-125b-2, miR-145-3p, miR-299-5p,
miR-154, miR-564, miR-495, miR-1271, miR-139-3p,
miR-129-3p, miR-548i, and miR-329. To establish the minimum
number of miRNAs that distinguish the tumors from normal
breast tissues, an “miRNA signature” was established by
assessing 10 miRNAs (Figure 1B).
To confirm our proposed “miRNA signature”, we used a
different series of patients (series 2) and a distinct array
platform (FEBIT). All miRNAs were also confirmed in the
second series of patient samples, with the exception of miR-21
(Table S3). Moreover, in this second series of patient samples,
miR-125b was observed to be significantly downregulated
(Table S3).
To independently validate miR-125b downregulation, the
levels of miR-125b in breast cancer patient samples from
series 1 were also analyzed by qRT-PCR (Figure 1C). The
expression of miR-125b was compared with the pathological
characteristics of the breast cancer patients, including age,
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tumor size, grade of differentiation, presence of lymph node
metastases, number of affected nodules, presence of distant
metastases, and the molecular classification of the tumors as
described (luminal A, luminal B, HER2+, and triple negative)
[28]. Because only 6% of tumors were HER2+ and 14% of
tumors were triple negative in our series (series 1), we consider
the results regarding molecular classification to be preliminary
(data not shown). For statistical conclusions regarding the
molecular classification of the tumors, a larger series of
patients would be required to increase the number of these
infrequent tumor subtypes (i.e., HER2+ and triple negative).
Overall, miR-125b did not correlate with any pathological
characteristics and was confirmed to be an miRNA consistently
downregulated in breast cancer patients. Therefore, we
focused on further characterization of miR-125b in breast
cancer tumor suppression.
miR-125b decreases cell proliferation and anchorage-
independent cell growth in mammary cells
To thoroughly investigate the biological effects of the most
significantly dysregulated miRNA in breast tumors, miR-125b
was stably overexpressed in MCF7, MDA-MB-231, and HMEC
cell lines, which have varying degrees of malignancy. This
experiment was performed to determine whether the biological
effect of miR-125b differs between normal and tumorigenic
cells. First of all, we analyzed by qRT-PCR the endogenous
expression level of miR-125b in a panel of cancer cell lines and
Figure 1.  The miRNA array in breast cancer patients.  (A) A total of 35 significantly dysregulated miRNAs were differentially
expressed in tumor (T) and normal (N) breast tissues (pool A and pool B) (p < 0.05) (see Materials and Methods). (B) The miRNA
signature of differentially expressed miRNAs in breast cancer patients. To establish the miRNA signature, miRNAs that were
differentially expressed between the two classes of tissues were compared with a t-test (p < 0.01). N/T: The numbers indicate the
mean fold up- or downregulation in the normal tissue with respect to the tumor tissue. The most significantly deregulated miRNA is
miR-125b, which shows more than a 5-fold downregulation in tumor tissue. (C) qRT-PCR of miR-125b in the patients analyzed in
Figure 1A. The standard deviation is indicated. ***p < 0.001.
doi: 10.1371/journal.pone.0076247.g001
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compared these levels with those of normal HMEC cells
(Figure 2A, upper panel). To validate the ectopic expression of
miR-125b in the breast cancer cells MCF7, MDA-MB-231, and
normal HMEC cells, qRT-PCR was employed to measure the
expression levels of miR-125 by comparing miRVec-125b- and
miRVec-GFP-infected cells (Figure 2A, lower panel). Parental
MCF7 cells (non-infected) were tested in parallel with the
infected cells and were found to behave like miRVec-GFP-
infected cells (data not shown).
Second, to confirm miR-125b expression, we also analyzed
proteins whose corresponding 3’-UTR mRNAs had been
previously described to directly interact with miR-125b, such as
p53, p-AKT, p-MAPK, and members of the E2F family
[15,29,30] (Figure S1A and data not shown). Our results
confirm the downregulation of p53 (the best known miR-125b
target [31]) in the MCF7 and HMEC cells infected with
miRVec-125b in comparison with miRVec-GFP-infected cells
(which have wild-type p53). However, no differences in p53
levels were observed in MDA-MB-231 cells (mutant p53) (data
not shown). As expected, other proteins related to the p53
pathway, such as p21CIP1 and HDM2, were also affected in
MCF7 and HMEC cells (Figure S1A and data not shown). No
differences in p-AKT, p-MAPK, E2F1, and E2F2 were observed
in any cell line included in our study (Figure S1A and data not
shown).
After establishing the miR-125b expression levels in MCF7,
MDA-MB-231, and HMEC cells, we examined the cell
proliferation capability related to miR-125b. Our results showed
that overexpression of miR-125b significantly decreased cell
proliferation (Figure 2B and 2C, Figure S1B, and data not
shown). To identify the potential mechanism responsible for the
observed effects of miR-125b on cell proliferation, we
performed senescence and cell cycle analysis and evaluated
apoptosis rates in the three cell lines transduced with
miRVec-125b or miRVec-GFP. For all three cell lines, the
decrease in cell proliferation was not due to a senescence
phenotype because we did not observe senescence-
associated -galactosidase activity (Figure S1C and data not
shown). Ectopic expression of miRVec-125b induced G2/M cell
cycle arrest in selected cell lines (Figure 2E). In addition to the
increased number of cells accumulating in the G2/M phase,
miRVec-125b overexpression induced apoptosis in MDA-
MB-231 cells (Figure 2D and Figure S2A). In contrast, there
were no differences in the apoptosis rates between cells
overexpressing miRVec-125b and miRVec-GFP in MCF7 and
HMEC cell lines (Figures S2A and S2B).
On the other hand, to determine the putative tumor
suppressor role of miR-125b, we tested its ability to reverse
transformation by performing soft agar colony transformation
assays. Our results showed that overexpression of miR-125b
decreased colony numbers by the order of 80% and 75%,
respectively, in MCF7 and MDA-MB-231 cells expressing
miRVec-125b compared with miRVec-GFP (Figure 2F).
Therefore, miR-125b dramatically decreased the anchorage-
independent cell growth ability of MCF7 and MDA-MB-231
cells.
miR-125b directly targets ENPEP, CK2-α, CCNJ, and
MEGF9
By using major prediction software (PicTar, TargetScan,
miRanda, and DIANA-microT), the potential binding sites of
miR-125b in the 3’-UTR mRNAs of ENPEP, CK2-α, CCNJ, and
MEGF9 were predicted. Next, we sought to analyze whether
miR-125b is able to regulate the expression of these proteins.
Western blotting analysis revealed that the levels of the
predicted target proteins ENPEP, CK2-α, CCNJ, and MEGF9
were decreased in miRVec-125b-overexpressing MCF7, MDA-
MB-231, and HMEC cells, with the exception that CCNJ is not
expressed in HMEC cells (Figure 3A). Of note, in the HMEC
cells, the cell cycle proteins CCND1 and CCNB1 were
downregulated compared to MCF7 and MDA-MB-231 cells
(Figure 3B).
To determine whether the ENPEP, CK2-α, CCNJ, and
MEGF9 proteins were downregulated because their 3’-UTR
mRNAs were direct targets of miR-125b, a luciferase assay
was performed in HEK293T cells, which express low levels of
endogenous miR-125b (Figure 2A, upper panel). Therefore,
this cell model may clearly reflect the biological effects of the
expression of miR-125b mimics. For this purpose, we
constructed a reporter vector consisting of the luciferase coding
sequence followed by the wild-type or mutant 3’-UTR of the
putative targets of miR-125b and used two different
cotransfection approaches (see Materials and Methods; Figure
S4).
First, we studied the effect of miR-125b mimics and
anti-125b on the wild-type pCI-3’-UTR constructs of ENPEP,
CK2-α, CCNJ, and MEGF9. In all cases, cotransfection
experiments showed that luciferase expression in those
constructs containing the wild-type form of 3’-UTR-ENPEP, 3’-
UTR-CK2-α, 3’-UTR-CCNJ, and 3’-UTR-MEGF9 was
significantly decreased upon transfection of miR-125b mimics,
but not the negative control (Figure 3C). More importantly,
similar effects on any of the wild-type pCI-3’-UTR mRNA
constructs were not observed in the presence of anti-125b
(Figure 3C). To confirm the inhibitory function of anti-125b on
endogenous miR-125b expression in HEK293T cells, qRT-PCR
was performed. Our results showed that anti-125b inhibited
miR-125b expression efficiently in a dose-dependent manner
(Figure S3B).
Second, we cotransfected miR-125b mimics or scrambled
negative control with each luciferase construct containing the
wild-type or mutant 3’-UTR mRNAs. Our results showed that
miR-125b mimics significantly decreased the luciferase activity
of all constructs containing the wild-type 3’-UTR mRNAs
compared to control cells, but there was no decrease in
luciferase activity in cells expressing the luciferase construct-
containing mutant 3’-UTR mRNAs of ENPEP and CCNJ
(Figure 3D). In the case of the mutant 3’-UTR mRNAs of
MEGF9 and CK2-α, luciferase activity did not decrease
significantly in cells expressing the specific mutant constructs
pCI-M654-3’-UTR-MEGF9 and pCI-M210-3’-UTR-CK2-α,
respectively, upon cotransfection with miR-125b mimics (Figure
3D). In each case, the experiments were performed in
triplicate. The results of one representative experiment out of
3–4 independent experiments are shown. Overall, our results
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Figure 2.  miR-125b expression decreases cell proliferation and anchorage-independent cell growth in mammary cells.  (A)
Upper panel: miRNA expression levels of miR-125b assessed by qRT-PCR in different cell lines. The graph shows data normalized
to RNU24 levels. The relative expression of miR-125b normalized to RNU24 was calculated with the 2-ΔΔCt method. HEK293T cells
were assigned the value of 1 as they express the lowest relative RNA level of miR-125b in comparison with the other cells lines
shown. Lower panel: miRNA expression levels of miR-125b assessed by qRT-PCR in different cell lines. miRVec-125b-
overexpressing cells compared to miRVec-GFP control cells in MCF7, MDA-MB-231, and HMEC cells. These cell lines were pooled
heterogeneous clones of the indicated genes after stable expression and selection with blasticidin for 12 days. (B) Cell numbers
upon miRVec-125b overexpression compared with those of miRVec-GFP control cells in the indicated cell lines after stable
expression and selection of the indicated genes with blasticidin for 12 days. (C) Phenotypic morphology of miRVec-GFP- and
miRVec-125b-transduced MCF7 cells (right panel) and crystal violet staining of miRVec-GFP- and miRVec-125b-transduced MCF7
cells (left panel). Cells were selected as indicated in B. (D) Apoptosis rates analyzed by FACS of miRVec-GFP- and miRVec-125b-
transduced MDA-MB-231 cells. Note the increases in early (1.3 ◊ 38.9%) and late (2.6 ◊ 26.3%) apoptosis in miRVec-GFP- and
miR-125b-overexpressing cells. (E) The cell cycle profiles of miRVec-GFP- and miRVec-125b-transduced HMEC, MCF7, and MDA-
MB-231 cells. miRVec-GFP-HMEC (G0/G1, 66.2%; S, 7.6%; G2/M, 26.2%) versus miRVec-125b-HMEC (G0/G1, 54.3%; S, 8.2%;
G2/M, 37.4%); miRVec-GFP-MCF7 (G0/G1, 75.8%; S, 18.3%; G2/M, 5.8%) versus miRVec-125b-MCF7 (G0/G1, 48.9%; S, 22.8%;
G2/M, 28.2%), and miRVec-GFP-MDA-MB-231 (G0/G1, 52.1%; S, 36%; G2/M, 11.9%) versus miRVec-125b-MDA-MB-231 (G0/G1,
46.9%; S, 30.5%; G2/M, 22.7%) (F) Representative images of colonies of the soft agar colony assay in miRVec-GFP- and
miRVec-125b-transduced MCF7 cells. ***p < 0.001.
doi: 10.1371/journal.pone.0076247.g002
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Figure 3.  miR-125b directly targets ENPEP, CK2-α, CCNJ, and MEGF9.  (A) Western blot analysis of MEGF9, ENPEP, CCNJ,
and CK2-α (subunits α and α’) in miRVec-GFP- and miRVec-125b-transduced MCF7, MDA-MB-231, and HMEC cells. (B) Western
blot analysis of cell cycle proteins CCNB1 and CCND1 in miRVec-GFP- and miRVec-125b-transduced MCF7, MDA-MB-231, and
HMEC cells. (C) The relative luciferase activity of HEK293T cells transfected with miR-125b mimics, anti-125b, or scrambled control
in the presence of the wild-type luciferase pCI-3’-UTR constructs of ENPEP, CK2-α, CCNJ, and MEGF9 mRNAs. HEK293T cells
were transfected with Lipofectamine 2000 and the final concentration of the scramble, miR-125b mimics, and anti-125b was 30 nM.
The luciferase plasmids and the pCI or pCI-3’-UTR for each indicated gene were used at a final concentration of 100 ng; the Renilla
plasmid was used at 10 ng. (D) The relative luciferase activity of HEK293T cells transfected with miR-125b mimics or scrambled
control in the presence of the luciferase constructs containing the wild-type or mutant form of 3’-UTR-ENPEP, 3’-UTR-CK2-α, 3’-
UTR-CCNJ, and 3’-UTR-MEGF9 mRNAs (*p < 0.05, **p < 0.01, ***p < 0.001).
doi: 10.1371/journal.pone.0076247.g003
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revealed that miR-125b does indeed repress the expression of
ENPEP, CK2-α, CCNJ, and MEGF9 by direct interaction of
miR-125b with their respective 3’-UTR mRNAs.
miR-125b inhibition promotes cell proliferation and
upregulation of miR-125b targets
To confirm that miR-125b decreases cell proliferation and
causes downregulation of novel targets of miR-125b, namely
ENPEP, CK2-α, CCNJ, and MEGF9, functional inhibition of
endogenous miR-125b with anti-125b oligonucleotides was
performed. For this purpose, we transiently transfected MCF7
and MDA-MB-435 cells with anti-125b or a scrambled negative
control. MDA-MB-435 cells were selected because miR-125b
levels have been reported to be approximately 20 times higher
than in MCF7 and HEK293T cells [32], an observation
corroborated by our study (Figure 2A, upper panel).
First, we verified the functionality of the anti-125b molecules
in MCF7 and MDA-MB-435 cells. We observed that the
inhibitory effect of anti-125b on endogenous miR-125b
expression in MCF7 and MDA-MB-435 cell lines was similar to
that of HEK293T cells (Figure S3 and data not shown).
Moreover, to confirm the effects of anti-125b at the protein
level, we checked the expression of a previous validated
miR-125b target, p53, in MCF7 cells. p53 protein was
upregulated in the presence of anti-125b expression (data not
shown). As expected, functional inhibition of endogenous
miR-125b significantly increased the proliferation of MCF7 cells
compared to the negative control (Figure 4A and 4B). This
increase in proliferation was accompanied by an upregulation
in the protein expression of the identified novel miR-125b
targets, ENPEP, CK2-α, CCNJ, and MEGF9 (Figure 4C).
Therefore, anti-125b transfection reversed the effects of
miR-125b on cell proliferation and protein expression. In MDA-
MB-435 cells, increases in CK2-α (both subunits α and α’) and
MEGF9 protein levels were observed, as expected for direct
mRNA targets of miR-125b (Figure 4D). Moreover, we
observed that MDA-MB-435 cells did not express CCNJ and
ENPEP, a fact that may be associated with their high miR-125b
levels (data not shown).
ENPEP, CK2-α, CCNJ, and MEGF9 knockdown
recapitulate the biological effects of miR-125b
expression
After identifying the 3’-UTRs of ENPEP, CK2-α, CCNJ, and
MEGF9 mRNAs as miR-125b targets, we then examined
whether repression of these proteins by siRNAs mimicked the
effects of miR-125b expression. To understand the contribution
of each protein to the proliferation arrest induced by miR-125b
expression, the siRNAs targeting ENPEP, CK2-α, CCNJ, and
MEGF9, or a scrambled siRNA control, were transiently
expressed in MCF7 cells. These siRNAs were transfected into
MCF7 cells because the endogenous miR-125b levels were
lower in MCF7 cells than other cells lines (Figure 2A, upper
panel). Therefore, the levels of some miR-125b targets (such
as CCNJ) were higher in MCF7s than in MDA-MB-231 or
HMEC cells (which lack CCNJ expression) (Figure 3A).
The effectiveness and specificity of each siRNA in reducing
the protein levels upon 72 h of transfection were initially
confirmed by western blot analysis (Figure 5A). With CK2-α
inhibition, the ER- protein was also assessed as a control
protein because ER- is a target protein of CK2-α and is thus
expected to be downregulated upon CK2-α inhibition [33]. As
expected, ER- protein expression was diminished upon CK2-α
downregulation (data not shown). The expression of an siRNA
pool for each protein decreased proliferation by more than 60%
in the case of siCK2-α, siCCNJ, and siMEGF9. However,
siENPEP inhibited cell proliferation by approximately 80%
(Figure 5B and 5C). The reduction in proliferation induced by
the inhibition of ENPEP, CK2-α, CCNJ, and MEGF9 was
accompanied by an increase in G2/M arrest (Figure 5D). In
addition, apoptosis analysis was performed upon transfection
of each siRNA in MCF7 cells. Repression of each protein did
not cause an increase in apoptosis rates compared to
scrambled siRNA-expressing control cells (Figure S5A).
To confirm these observations and to eliminate the possibility
of off-target effects, we inhibited the genes described above
with a different approach, that of shRNA. MCF7 cells were
stably transfected with the corresponding shRNAs against each
gene and were selected with puromycin for 3 days. A total of
four different shRNAs against each gene were used. Therefore,
four different cell lines were generated for each gene
knockdown (each corresponding to a different shRNA
construct). Only those shRNAs that strongly inhibited the target
protein were used for further proliferation studies (Figure S5B).
The growth curve, cell cycle, and apoptosis profiles were
analyzed for each cell line. The results confirmed our previous
observations with the siRNA treatments (data not shown).
ENPEP, CK2-α, CCNJ, and MEGF9 in breast tumors
To investigate the importance of ENPEP, CK2-α, CCNJ, and
MEGF9 proteins in breast tumors, we studied the expression of
each protein by western blot analysis in 25 breast cancer
patient samples (series 3; Figure 6A and 6B). In addition, CK2-
α was also detected by IHC in the samples from our initial
series of 50 patients (series 1).
ENPEP protein was not detected in any patient in normal
tissue but was expressed in the corresponding tumor tissues in
56% of patients (Figure 6A). CK2-α was expressed in normal
and tumor tissues, but its expression was higher in the tumors,
a result that was found on both western blot analysis and IHC
(Figure 6B and 6C). In comparison with the levels of normal
tissue, CK2-α was overexpressed in the tumor tissue of 56% of
the patient samples by IHC and overexpressed in 40% of the
patient samples by western blot analysis (Figure 6). CCNJ was
expressed in 20% of the breast cancer patient samples and
was not detected in the normal breast tissue of any patient
(Figure 6A and 6B). Finally, in the 25 frozen biopsies, 32% of
the samples exhibited MEGF9 overexpression (Figure 6A and
6B). MEGF9 was not expressed in any patient in normal breast
tissue but was detected in the corresponding tumor samples by
western blot analysis (Figure 6A and B).
In addition, correlation analysis between miR-125b levels
(analyzed with qRT-PCR) and the expression of ENPEP, CK2-
α, CCNJ, and MEGF9 protein was studied in 25 breast cancer
patient samples (series 3). An inverse correlation between
miR-125b and the expression of ENPEP and CK2-α proteins
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was identified (Figure 7A and 7B). No significant results were
detected for MEGF9 and CCNJ, although a clear trend for the
MEGF9 protein could be observed (Figure 7C and data not
shown).
Furthermore, we investigated whether the expression of
ENPEP, CK2-α, CCNJ, and MEGF9 proteins correlated with
the pathological characteristics of the patients. Of note, CK2-α
expression correlated with the number and presence of lymph
node metastases (Figure 7D, and data not shown).
Discussion
In this study, we present data from genome-wide miRNA
expression profiling in different sets of normal and cancerous
breast tissues. Our analyses, which involved the most recently
identified miRNAs, provide an updated overview of miRNA
expression in breast cancer. In the last decade, several
studies, performed to establish which miRNAs are aberrantly
expressed in breast cancer, have identified key miRNAs in
breast cancer progression, as well as miRNA signatures
associated with the different molecular types of breast cancer
[11,34-36]. In the present work, we identified a total of 35
miRNAs aberrantly expressed in the tumor sample compared
with normal breast tissue from the same patient (Figure 1A).
We confirmed the downregulation or upregulation of the most
dysregulated miRNAs from our study, including potential
oncogenic miRNAs (miR-21, miR-96, miR-141, miR-106b,
miR-130b, and miR-340) and potential tumor suppressor
miRNAs (miR-125b, miR-451, miR-99a, miR-145, miR-100,
miR-195, miR-497, miR-376c, miR-486-5p, miR-204, miR-218,
Figure 4.  miR-125b inhibition promotes cell proliferation and upregulation of ENPEP, CK2-α, CCNJ, and MEGF9.  (A) MCF7
and MDA-MB-435 cell numbers after transfection with anti-125b or scrambled control. Cells were transfected with the indicated
oligonucleotides at a final concentration of 80 nM each by using HiPerFect reagent. After 72 h of transfection, the cells were
counted, photographed, and collected for protein extraction. *p < 0.05, **p < 0.01. (B) The phenotypic effects on cell proliferation of
anti-125b and scrambled control in MCF7 and MDA-MB-435 cells. The transfection conditions were the same as those described in
A. (C) Western blot analysis of ENPEP, CK2-α, CCNJ, and MEGF9 in MCF7 cells transfected with anti-125b or scrambled control.
The transfection conditions were the same as those described in A. (D) Western blot analysis of MEGF9 and CK2-α in MDA-
MB-435 cells transfected with anti-125b or scrambled control. The transfection conditions were the same as those described in A.
doi: 10.1371/journal.pone.0076247.g004
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miR-381, miR-489, miR-125b-2, miR-299-5p, miR-154,
miR-564, and miR-495) reported in previous studies, which
further validate our array [11,36-38]. Several of these miRNAs
are potential biomarkers for the diagnosis of preinvasive breast
lesions [34,39,40]. To our knowledge, our study is the first to
propose several miRNAs involved in breast tumorigenesis as
potential oncogenic or tumor suppressor miRNAs, including
miR-1274a, miR-1274b, miR-1260, miR-329, miR-139-5p,
miR-145-3p, miR-1271, miR-139-3p, miR-564, miR-551b,
miR-129-3p, and miR-548i. The relevance and importance of
these miRNAs should be examined in future studies.
We have also established a profile of 10 significantly
dysregulated miRNAs as a fingerprint of breast tumorigenesis.
miRNA expression profiling studies with samples from an
independent series of patients confirmed all miRNAs contained
in the miRNA signature, with the exception of miR-21. The fact
that the second series was analyzed at the level of pools (see
Materials and Methods) might have masked the important role
of miR-21 in breast cancer that was found previously by us and
others (Figure 1A and 1B) [23,41]. These results support the
proposed list of 10 miRNAs as a reliable fingerprint to assess
breast tissue malignancy.
We found that miR-125b is the most significantly
downregulated miRNA in breast cancer patients. The
prognostic role of miR-125b has been previously suggested in
relation with patient survival [18], a parameter that will be
analyzed in our series once 5 years have elapsed from the
surgery.
miR-125b has been demonstrated to be involved in several
diseases, such as psoriasis, Alzheimer’s disease, and cancer.
Figure 5.  siRNA-mediated ENPEP, CK2-α, CCNJ, and MEGF9 knockdown recapitulates the biological effects of miR-125b
expression.  (A) Western blot analysis of ENPEP, CK2-α, CCNJ, and MEGF9 upon transfection of the indicated siRNAs and
scrambled control in MCF7 cells. Cells were transfected with the indicated pools of siRNAs at final concentrations of 30 nM by using
HiPerFect transfection reagent. After 72 h of transfection, the cells were counted, photographed, and either collected for protein
extraction or trypsinized for FACS analysis. (B) Cell numbers after 3 days of transfection with the indicated siRNAs. (C) Images of
phenotypic effects on cell proliferation after 3 days of transfection with the indicated siRNAs in MCF7 cells. (D) The cell cycle
profiles of MCF7 cells after expression with the indicated siRNAs or scrambled control. Scramble (G0/G1, 68.9%; S, 19.6%; G2/M,
11.7%), siCCNJ (G0/G1, 44.2%; S, 16.5%; G2/M, 39.2%), siMEGF9 (G0/G1, 53.2%; S, 18.5%; G2/M, 28.2%), siENPEP (G0/G1,
44.1%; S, 16.5%; G2/M, 39.3%), and siCK2-α (G0/G1, 43.8%; S, 22.3%; G2/M, 33.9%). Cells were transfected according to the
conditions described in A. ***p < 0.001.
doi: 10.1371/journal.pone.0076247.g005
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It also modulates some key proteins that are involved in
tumorigenesis [13,15,42,43]. However, its role in breast cancer
is only now emerging, though downregulation of miR-125b in
breast tumors has been described in several reports
[11,18,34,44]. Consistent with previous studies [18,30], we
corroborated the tumor suppressor role of miR-125b in breast
tumorigenesis by demonstrating the following: (1) its strong
downregulation in breast tumors, (2) its effect on decreasing
the proliferation of mammary cell lines with different degrees of
malignancy, and (3) its ability to decrease cellular
transformation. We found that the decrease in proliferation
observed with miR-125b expression elicits a different response
depending on the cell line. Thus, apoptosis is strongly induced
in MDA-MB-231 cells, and G2/M cell cycle arrest is induced in
HMEC, MCF7, and MDA-MB-231 cells upon miR-125b
expression. This finding highlights the functional plasticity of
miR-125b according to the cellular context. Importantly, we
included HMEC, which are wild-type cells of epithelial origin.
The apoptosis induction observed in MDA-MB-231 cells may
be due to alterations associated with the nature of highly
tumorigenic cells, in contrast to MCF7 or normal HMEC cells.
miR-125b can regulate apoptosis via direct repression of
proapoptotic regulators, such as p53, Bak1, and Puma, or
antiapoptotic regulators, such as Bcl2, Mcl-1, and Bcl-w,
promoting inhibition or induction of apoptosis depending on the
cell context [17,29,31,45,46]. Accordingly, we observed
downregulation of known miR-125b targets, such as p53, along
with their associated partners and targets (e.g., hdm2 or
p21CIP1) in the cell lines with wild-type p53 (HMEC and MCF7)
[29]. However, the phenotypic effect observed in our cells upon
miR-125b overexpression could not be due to p53
downregulation itself. Moreover, other proteins reported to be
Figure 6.  The expression of ENPEP, CK2-α, CCNJ, and MEGF9 in breast tumors.  (A) Table showing a summary of ENPEP,
CK2-α, CCNJ, and MEGF9 expression by western blot in 25 breast tumors. The total percentages of patients that express/
overexpress these proteins are shown. 0, lack of expression; 1, positive expression/overexpression. (B) Protein expression
analyzed by western blot of ENPEP, CK2-α, CCNJ, and MEGF9 in four breast cancer patients is indicated. (C) IHC analysis of two
patients overexpressing CK2-α. Note the difference in the staining of the tumor (T) in comparison with that of normal (N) breast
tissue.
doi: 10.1371/journal.pone.0076247.g006
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modulated by miR-125b, such as p-ERK, p-AKT, and members
of the E2F family, were not affected in our cells [15].
To elucidate the proteins responsible for this effect, we
explored other potential oncogenic proteins that could be
modulated by miR-125b. Importantly, we found novel miR-125b
targets, including ENPEP, CK2-α, CCNJ, and MEGF9.
Moreover, the effects of miR-125b on the same target proteins
in the three different cell lines (with the exception of CCNJ,
which is not expressed in HMEC cells) appear to be a
generalized response in mammary cells. Other cell cycle
proteins that are not targets of miR-125b were also
downregulated, such as CCND1 and CCNB1. This may reflect
the cell cycle arrest that is observed in the G2/M phase in the
normal cells (HMEC).
The relevance of ENPEP, CK2-α, CCNJ, and MEGF9
proteins in cancer is gradually being revealed. Cell surface
peptidases, including ENPEP, play key roles in the regulation
of growth, differentiation, and signal transduction of many
cellular systems by modulating the activities of the peptide
substrates and regulating access to their receptors [47,48].
ENPEP is considered to be an essential and highly specific
enzyme, which metabolizes and inactivates bioactive peptides
such as angiotensin II (AngII) in the renin-angiotensin system
[49]. The putative oncogenic role of ENPEP was demonstrated
by Marchio and colleagues [50], who showed that ENPEP
regulates blood vessel formation in mice and can serve as a
functional vascular target. In addition, ENPEP is expressed in
neoplastic lesions of the uterine cervix, and its levels are
upregulated as the lesions progress from cervical intraepithelial
Figure 7.  ENPEP, CK2-α, CCNJ, and MEGF9 proteins and their correlation with miR-125b expression in breast cancer
patients.  (A) Correlation between miR-125b expression and ENPEP. (B) Correlation between miR-125b expression and CK2-α.
(C) Correlation between miR-125b expression and MEGF9. (D) Correlation between CK2-α expression and the number of lymph
node metastases (0, negative CK2-α expression; 1, positive CK2-α expression). (E) Schematic representation of how miR-125b
might modulate these proteins and their possible interactions. *p < 0.05.
doi: 10.1371/journal.pone.0076247.g007
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neoplasms to invasive squamous cell carcinomas [51]. Here,
we demonstrated for the first time that ENPEP knockdown has
a strong effect on the decreased proliferation of MCF7 cells,
which contrasts with the observations from the inhibition of
other targets modulated by miR-125b, such as CK2-α, CCNJ,
or MEGF9. Moreover, we discovered that ENPEP is
overexpressed in a relatively high percentage of breast cancer
patients (56%). Accordingly, ENPEP expression is absent in
normal cells and is overexpressed in cancer cell lines
compared with normal cells of mammary origin (data not
shown).
The CK2 protein is a highly conserved serine/threonine
kinase. It is ubiquitous in eukaryotic cells, and mainly exists as
a tetrameric complex consisting of two catalytic subunits (α, α’)
and two regulatory β subunits. CK2-α is a remarkable
multifunctional protein kinase with hundreds of substrates,
many of which are critically involved in the maintenance of cell
viability in normal cells during embryogenesis, and it regulates
multiple pathways, including the PI3K/AKT and WNT signaling
cascades, NF-κB, and the DNA damage response [33]. CK2-α
is considered a prototypical non-oncogene needed for
maintaining the transformed phenotype. CK2-α is upregulated
in some cancers, including breast cancer, and is involved in
modulating proliferation and invasion [52-54]. In the present
study, we have shown that CK2-α knockdown decreases the
proliferation of MCF7 cells by inducing G2/M cell cycle arrest.
This finding is consistent with a previous report that showed
that treatment of breast cancer cells with a chemical inhibitor of
CK2-α induced G2/M cell cycle arrest [55]. Moreover, we have
found that CK2-α protein is expressed in 40%–56% of breast
cancer patients.
MEGF9 is a transmembrane protein that is strongly
expressed in the nervous system and is regulated during
development [56]. A study has suggested its possible
association with cancer, demonstrating a link between a
decrease in MEGF9 expression and the aggressiveness of soft
tissue tumors [57]. Our results are not, however, consistent
with the results of Cunha et al. [57], possibly because that
study focused on soft tissue tumors as opposed to the solid
tumors that we analyzed here. In addition, the results of Cunha
et al. [57] were based solely upon RNA expression data, which
requires further confirmation by protein analysis. For the first
time, our current data show that MEGF9 is capable of
regulating cell proliferation because MEGF9 knockdown—by
different strategies—significantly decreased the proliferation of
MCF7 cells. Moreover, we found that MEGF9 protein is
expressed in 32% of tumors, a finding that could have
therapeutic implications in breast cancer patients as this
protein is a membrane receptor whose blockage might alter the
proliferative signal.
Finally, CCNJ, a protein that controls cell mitosis, is a
distinctive cyclin characterized by its exclusive maternal
expression pattern, which suggests that it may regulate
oogenesis and embryogenesis [58,59]. CCNJ is not a
ubiquitous cyclin because it is not expressed in some tissues or
in certain cancer cell lines with origins other than mammary
tissue (www.proteinatlas.com and data not shown). Moreover,
its peculiar expression in the cytoplasm also differentiates it
from the other cyclins (www.proteinatlas.com). CCNJ is a
putative oncogene because is embedded in a cluster of genes
found dysregulated in pediatric high-risk B-precursor acute
lymphoblastic leukemia [60]. The fact that CCNJ is not
expressed in normal HMEC cells but is expressed in certain
cancer cells (MCF7 and MDA-MB-231) and that CCNJ
silencing decreased the proliferation of MCF7 cells by inducing
G2/M cell cycle arrest is consistent with the proliferative role of
CCNJ suggested by other studies in Drosophila and prostate
cancer cells [59,61]. Importantly, CCNJ expression is present
in 20% of patients with breast cancer, exclusively in the
malignant tissues. Therefore, we suggest a potential oncogenic
role of CCNJ in breast tumorigenesis.
The aim of analyzing ENPEP, CK2-α, CCNJ, and MEGF9
expression in breast tumors was to clarify their association with
miR-125b. Remarkably, miR-125b is inversely correlated with
ENPEP and CK2-α expression in breast tumors. miR-125b also
trends towards a correlation with MEGF9, though this
association needs to be confirmed by further studies. Our
results establish these proteins as relevant in vivo miR-125b
targets with potential important clinical implications in breast
tumorigenesis. Specifically, CK2-α overexpression is
associated with the presence and number of lymph node
metastases. This fact underscores the usefulness of CK2-α as
a prognostic marker for breast tumors, as previously suggested
for colon and breast cancers [62,63]. Regarding the lack of an
association between miR-125b and CCNJ expression, it is
tempting to hypothesize that miR-125b may correlate with
CCNJ levels in certain tumorigenic cells (e.g., cancer stem
cells). Several reports describe a stemness role for miR-125b
and CCNJ, which would explain why its expression is
associated with stem cells but not mature differentiated cells
[64-66]. Apart from the overexpression of ENPEP, CK2-α,
CCNJ, and MEGF9 in certain breast cancer patients, the
potential oncogenic roles of these proteins is supported by the
fact that their downregulation causes significant inhibition of
cell proliferation. Our data suggest that in some percentage of
patients with breast cancer tumors, miR-125b downregulation
consistently occurs; this involves a repression of the genes that
code for ENPEP and CK2-α, and potentially MEGF9 and CCNJ
(Figure 7E). Therefore, miR-125b modulates the different
molecular pathways associated with these proteins. Moreover,
dysregulation of these oncogenic proteins might contribute to a
great extent to the tumorigenic phenotype, which is explained,
at least in part, by miR-125b downregulation. The pathways in
which these proteins are involved appear to play important
roles in cancer cells derived from breast tissues, regardless of
their ER-α or p53 status (which differ among the cell lines
studied). Expanding our knowledge of the pathways that are
used by these proteins to decrease proliferation in vivo (e.g.,
angiogenesis, cell cycle, or receptor signaling) would open new
avenues for the treatment of breast cancer.
Supporting Information
Figure S1.  miR-125b expression in HMEC and MCF-7 cells.
(A) Expression of the cell cycle-related proteins p53, p21CIP1,
hdm2, and p16INK4A in HMEC cells expressing miRVec-GFP or
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miRVec-125b (left panel). Expression of p-AKT, p-MAPK,
E2F1, and E2F2 in miRVec-GFP- and miRVec-125b-
expressing HMEC cells (right panel). (B) 3T3 protocol in
miRVec-GFP- and miRVec-125b-expressing HMEC cells. (C)
miRVec-GFP- and miRVec-125b-transduced HMEC and MCF7
cells were stained with β-galactosidase to detect the presence
of senescent cells. A senescence-induced control is included
for each cell line. OHT, tamoxifen. **p < 0.01, ***p < 0.001.
(TIF)
Figure S2.  miR-125b expression and apoptosis analysis.
(A) Western blot analysis of PARP in the different cell lines
used in this study (HMEC, MCF7, and MDA-MB-231). (B)
Apoptosis rates analyzed by FACS of miRVec-GFP- and
miRVec-125b-transduced HMEC and MCF7 cells. The
percentages of cells in early (lower right panel) and late (upper
right panel) apoptosis are indicated for each cell line.
(TIF)
Figure S3.  Dose-response of anti-125b in HEK293T cells.
Inhibitory effects of different anti-125b concentrations (10–100
nM) on the endogenous levels of miR-125b, as assessed by
qRT-PCR. Note the progressive decrease in miR-125b
expression with the increasing levels of anti-125b.
(TIF)
Figure S4.  Different mutants of the 3’-UTRs of ENPEP,
CK2-α, CCNJ, and MEGF9. Alignment of the 3’-UTRs of
ENPEP, CK2-α, CCNJ, and MEGF9 mRNAs and the predicted
conserved miR-125 binding sites at the indicated positions. The
point mutations that were introduced in the 3’-UTR of each
mutant gene construct are indicated in bold. The seed
sequence is indicated in yellow.
(TIF)
Figure S5.  Knockdown of ENPEP, CK2-α, CCNJ, and
MEGF9. (A) Apoptosis detection by FACS upon transient
transfection of the indicated siRNAs and their controls. (B)
Western blot analysis of CCNJ and MEGF9 in scrambled
negative control MCF7 cells, shCCNJ-transduced MCF7 cells
(4 different shRNAs), and shMEGF9-transduced MCF7 cells (4
different shRNAs). shCCNJ (No. 2) and shMEGF9 (No. 1) were
selected for protein studies, as well as cell cycle, apoptosis,
and growth curve studies.
(TIF)
Table S1.  Description of primers used in this article.
(XLS)
Table S2.  Row data from miRNA arrays. The results from
the miRNA arrays for all miRNAs are shown for each patient
(T, tumor). Pools of normal tissue (N) are also indicated (pool
A, pool B, and pool C). Fold-change (FC) values are shown for
each miRNA, as well as the p value and p-adjusted value, as
described in the Materials and Methods. A logarithmic scale for
the T/N ratio is shown.
(XLS)
Table S3.  Differentially expressed miRNAs in an
independent series of patients. Pools of tumor and normal
tissue were analyzed in duplicate by different array platforms,
as described in the Materials and Methods. Green indicates the
miRNAs that were significantly downregulated in the tumor in
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